Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17807741 | 0.79 | — | — | |
| SCHEMBL19199989 | 0.76 | KDM4E (0.36) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL22419390 | 0.74 | CDK4 (0.35) | — | |
| SCHEMBL18237738 | 0.72 | PIK3CD (0.35) | ALDH1A1PIK3CD | |
| SCHEMBL22419395 | 0.71 | USP1 (0.41) | — | |
| SCHEMBL22419357 | 0.71 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL22419358 | 0.71 | PIK3CD (0.32) | PDE4BPIK3CD | |
| SCHEMBL5956295 | 0.66 | KDM4E (0.50) | KDM4EALDH1A1PDE4B | |
| SCHEMBL22419351 | 0.65 | KMT2A (0.35) | KDM4EALDH1A1PDE4B | |
| SCHEMBL19200859 | 0.64 | AURKA (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | KDM4E 796/4885ALDH1A1 3026/4885PDE4B 2300/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | KDM4E 646/4885ALDH1A1 3041/4885PDE4B 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.